Continuous Subcutaneous Lisuride Infusion — Competitive Intelligence Brief

Continuous Subcutaneous Lisuride Infusion (Continuous Subcutaneous Lisuride Infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine agonist. Area: Neurology.

phase 3 Dopamine agonist D1 and D2 dopamine receptors Neurology Small molecule

Target snapshot

Continuous Subcutaneous Lisuride Infusion (Continuous Subcutaneous Lisuride Infusion) — Axxonis Pharma AG. Lisuride is a dopamine agonist that activates dopamine receptors to improve motor symptoms and reduce involuntary movements in Parkinson's disease.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Continuous Subcutaneous Lisuride Infusion TARGET	Continuous Subcutaneous Lisuride Infusion	Axxonis Pharma AG	phase 3	Dopamine agonist	D1 and D2 dopamine receptors
Neupro	ROTIGOTINE	UCB	marketed	Nonergot Dopamine Agonist [EPC]	dopamine receptors	2007-01-01
ropinirole/L-dopa	ropinirole/L-dopa	GlaxoSmithKline	marketed	Dopamine agonist and dopamine precursor combination	Dopamine D2/D3 receptors (ropinirole); dopamine synthesis pathway (L-dopa)
ROP+L-Dopa	ROP+L-Dopa	GlaxoSmithKline	marketed	Dopamine agonist + Levodopa combination	Dopamine receptors (D2/D3); Dopamine pathway
Dopamine Agonists	Dopamine Agonists	Leiden University Medical Center	marketed	Dopamine agonist	Dopamine receptors (D1-D5)
DAM	DAM	Beijing Bozhiyin T&S Co., Ltd.	marketed	Dopamine agonist	Dopamine receptor
Pramipexole (Mirapex)	Pramipexole (Mirapex)	Massachusetts General Hospital	marketed	Dopamine agonist	D2 dopamine receptor, D3 dopamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine agonist class)

1. Sumitomo Pharma America, Inc. · 2 drugs in this class
2. University Hospital, Toulouse · 2 drugs in this class
3. Rennes University Hospital · 2 drugs in this class
4. Britannia Pharmaceuticals Ltd. · 1 drug in this class
5. Desitin Arzneimittel GmbH · 1 drug in this class
6. GlaxoSmithKline · 1 drug in this class
7. Intec Pharma Ltd. · 1 drug in this class
8. Leiden University Medical Center · 1 drug in this class
9. Ludwig-Maximilians - University of Munich · 1 drug in this class
10. Massachusetts General Hospital · 1 drug in this class